Financials results

Aanjaay Industries Limited (Formerly known as Kabra Drugs Limited) CIN:- L02423MP1989PLC005438 Regd Offc: 208 Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh, India, 452011 (Amount in ₹ Lakhs) Statement of Unaudited Standalone Financial Results for the Quarter Ended June 30, 2026 Quarter Ended Year Ended Sl No. Particulars 30th June, 2026 31st March, 2026 30th June, 2025 31st March, 2026 (Unaudited) (Audited) (Unaudited) (Audited) INCOME 1 Revenue from Operations 4 ,621.68 3,540.60 7 15.00 9 ,274.00 2 Other Income 7.65 11.31 1.62 4 9.27 3 Total Income 4,629.33 3 ,551.91 7 16.62 9 ,323.27 EXPENSES (a) Cost of materials consumed - - - - (b) Purchases of Stock-in-Trade 4 ,903.20 208.80 6 75.00 8 ,366.40 (c) Changes in inventories of finished goods, work-in-progress, and stock-in-trade (603.00) 3,097.80 - - (d) Employee benefit expense 2 3.72 34.56 3 7.81 1 46.59 (e) Finance Costs 0 .53 1.47 - 3 .00 (f) Depreciation and amortization expense 2 .06 1.75 0 .34 7 .11 (g) Other expenses 18.81 65.50 53.46 228.10 4 Total Expenses 4,345.32 3 ,409.89 7 66.60 8 ,751.20 5 Profit / (Loss) from operations before exceptional items Tax (3-4) 284.01 1 42.02 ( 49.98) 5 72.07 6 Exceptional Items - - 7 Profit / (Loss) before Tax (5 ± 6) 284.01 1 42.02 ( 49.98) 5 72.07 Tax Expense Current Tax 7 1.73 35.54 - 7 5.54 Deferred Tax Liability ( 0.02) 0.14 - 0 .55 Prior Period Tax Reversal - - 8 Total Tax Expenses 71.71 3 5.69 - 7 6.09 9 Net Profit / (Loss) after Tax (7 - 8) 212.30 1 06.33 ( 49.98) 4 95.98 10 Other Comprehensive Income (net of tax ) (i) Items that will not be reclassified to profit or loss - - - - (ii) Income tax relating to items that will not be reclassified to profit or loss - - - - (i) Items that will be reclassified to profit or loss - - - - (ii) Income tax relating to items that will be reclassified to profit or loss - - - - 11 Total Comprehensive Income for the period (9 ± 10) 212.30 1 06.33 ( 49.98) 4 95.98 12 Paid-up equity share capital (Face Value of Rs.10/- each) 2 ,370.79 2 ,370.79 2 ,370.79 2 ,370.79 13 Earnings Per Share (of Rs. 10/- each) (not annualised): (a) Basic 0 .90 0 .45 ( 0.21) 2 .09 (b) Diluted 0 .90 0 .45 ( 0.21) 2 .09 Notes: TheaboveresultswhicharepublishedinaccordancewithRegulations33ofSEBI(ListingObligation&DisclosureRequirements),2015havebeenreviewedbytheAuditCommitteeandapprovedby the Board of Directors at their respective meeting held on August 12th, 2026. The Statutory Auditors have carried out a limited review of the above financial result. 2 These financial results have been prepared in accordance with Ind AS 34 "Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. As the Company collectively operates only in one business Segment, hence, it is reporting its results in single Segment. Therefore, segment disclosure is not applicable. The Company does not have any subsidiary/ associate/ joint venture entity(ies) for the respective period. EPS is not annualized for the Quarterly results. The EPS has been computed based on weighted average number of equity shares outstanding for the respective periods The figures for the corresponding previous periods / year have been regrouped / reclassified wherever necessary. There were no exceptional and extra-ordinary items for the reporting period. 8 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the published year-to date figures up to the quarter ended December 31, 2025, which were subjected to limited review. For and on Behalf of the Board of directors of Aanjaay Industries Limited (Formerly known as Kabra Drugs Limited) Nanjappan Aravind Place : Chennai Managing Director Date : 12.08.2026 DIN: 01895602